Board Of Directors

Samuel J. Reich
Executive Chairman, Biscayne Neurotherapeutics

Mr. Reich is founder of the Reich Group, an early-stage biotechnology investment firm and is a co-founder and Executive Chairman of drug developer Biscayne Pharmaceuticals. Previously, he served as Executive Vice President of OPKO Ophthalmologics. Earlier in his career, Mr. Reich was a founder and Executive Vice President of Acuity Pharmaceuticals, where he oversaw research and development, business development and intellectual property management. Mr. Reich was instrumental in completing financings totaling about $25 million for Acuity, and he subsequently helped engineer its successful acquisition by OPKO Health. Mr. Reich received his BA degree with high honors from Clark University, where he was Phi Beta Kappa, and later pursued doctoral studies in molecular biology at the University of Pennsylvania.

Stephen Collins, MD, PhD
Director, President & Chief Executive Officer, Biscayne Neurotherapeutics

Dr. Collins was formerly President and Chief Executive Officer of Insero Health, a developer of novel drugs for epilepsy and pain that was acquired by Biscayne Pharmaceuticals, where Dr. Collins also served as President and CEO. Previously, he was CEO of NeuroTherapeutics Pharma, a developer of novel CNS therapies, and Chief Scientific Officer and Vice President, Clinical Affairs at specialty pharmaceutical company Ovation Pharmaceuticals, where he oversaw research and development, won FDA approval for the orphan drugs Sabril® and Onfi®, and directed multiple late stage and post-approval development programs in oncology and neuroscience. Ovation was acquired by Lundbeck in 2009. Prior to Ovation, Dr. Collins was Global Senior Director of CNS and Pain at Johnson & Johnson, overseeing early-stage development of neurologic, pain and psychiatric agents. At Abbott Laboratories, Dr. Collins developed drugs for CNS and pain indications and contributed to the FDA approval of the epilepsy drugs Depakote ER® and Depacon®. He earned an AB degree in biophysics at the University of California, Berkeley and MD and PhD degrees at Case Western Reserve University. Dr. Collins completed residency and fellowship training at the University of California, San Francisco, where he also served on the faculty.

Warren Lammert

Mr. Lammert is an officer and the past Chairman of the Epilepsy Foundation. He is a co-founder of the Epilepsy Therapy Development Project and Mr. Lammert is a founder, Principal and Chief Investment Officer of Granite Point Capital. Previously, he was at Janus Capital Group for 14 years, serving in several investment and senior management roles including Portfolio Manager of the Janus Mercury Fund. Earlier in his career, Mr. Lammert worked in equity research at Fred Alger Management. He serves on the Board of Directors of FACES (Finding a Cure for Epilepsy and Seizures) at New York University. Mr. Lammert received a BA degree from Yale University, a MSc degree with Distinction from the London School of Economics and is a Chartered Financial Analyst.

Carey Ng, PhD, MBA

Dr. Ng is a Managing Director of Mesa Verde Venture Partners and has over 10 years of investment and operating experience in the biomedical industry. Dr. Ng is a member of the firm’s Investment Committee and works with Mesa Verde portfolio companies as a director and member of the management team. Currently, Dr. Ng serves on the boards of Biscayne Neurotherapeutics, Paradigm Diagnostics and Satiogen Pharmaceuticals, where he is also the company’s Chief Operating Officer.  In addition, Dr. Ng is a board observer at Oncternal Therapeutics, Retrosense Therapeutics and Alastin Skincare.  Prior to Mesa Verde, Dr. Ng worked with biomedical startups including Salvaregen and AltheaDx, and at Abbott Laboratories, a large global healthcare company.  Dr. Ng received a PhD in Molecular & Medical Pharmacology from the University of California, Los Angeles and an MBA from the Rady School of Management at the University of California, San Diego.

Zafrira Avnur, PhD

Dr. Avnur is Chief Scientific Officer and a Partner at Quark Venture Inc. and a Vice President of Quark Venture USA in Boston. Prior to joining Quark in October 2016, she was the Global Head, Academic Collaborations in the Partnering unit at Roche. Previously, for more than 25 years. Dr. Avnur held positions of increasing responsibility in Roche’s research and development organization in its facilities in Palo Alto, California and Basel, Switzerland. These included Distinguished Scientist at Roche Bioscience, Disease Area Head for Osteoporosis, Head of Musculoskeletal Research, Director of Scientific Evaluation and Director of Biomarker Alliances.
Dr. Avnur has authored or co-authored more than 30 peer-reviewed scientific papers and holds a number of patents. She received a PhD from the Weizmann Institute (cell biology).in Israel and conducted postdoctoral research at Stanford University.